B. Braun Medical Secures FDA Approval for New Drug Delivery System Enhancements
B. Braun Medical Inc., a pioneering force in smart infusion therapy and pain management, has officially announced receiving approval from the U.S. Food and Drug Administration (FDA) for its Piperacillin and Tazobactam for injection in the innovative DUPLEX® Drug Delivery System. This marks a significant milestone, as Piperacillin and Tazobactam is among the most frequently used injectable antibiotics in the United States, and its introduction in this advanced delivery system promises to alter the landscape of antibiotic administration.
The DUPLEX Drug Delivery System is engineered to streamline the medication administration process. The system features a two-compartment container that maintains a pre-measured antibiotic and diluent separately until the healthcare provider is ready to deliver the dosage. By simply folding, squeezing, and shaking the container, medical professionals can efficiently reconstitute the medication at the bedside. This unique set-up reduces the time taken to prepare each dose by nearly four minutes, which translates to substantial labor savings for healthcare workers compared to both the Baxter Mini-Bag Plus Container System and traditional compounding.
Beyond efficiency, the DUPLEX system aims to enhance safety for patients. Its closed-system architecture significantly lowers the risk of contamination and medication errors, with a noted decrease in errors by 54% relative to standard compounding methods. Impressively, no thawing is necessary, and the system's contents can be safely stored at room temperature or within automated dispensing units.
Jeremy Greene, Senior Director of Marketing at B. Braun Medical, emphasized the company's commitment to improving operational efficiency for healthcare providers while aligning with their overarching goal to safeguard patient welfare. “We are excited to introduce Piperacillin and Tazobactam in our innovative DUPLEX Drug Delivery System, designed to save time, labor, and space, and reduce waste,” Greene stated. He highlighted that the DUPLEX Container is crafted without DEHP or PVC, reinforcing B. Braun’s commitment to patient safety and environmental sustainability.
The launch of Piperacillin and Tazobactam in the DUPLEX Drug Delivery System represents B. Braun's second significant release this year, following the Cefazolin 3g introduction in similar configurations. Both reinforced the company's dedication to expanding its product offerings in response to the pressing demand for effective medications. As the company plans to unveil an array of injectable drugs in the subsequent years, it strives to bolster its portfolio to meet evolving patient needs.
Piperacillin and Tazobactam for Injection and Sodium Chloride Injection combines the efficacy of piperacillin, a member of the penicillin antibiotic class, with tazobactam, a beta-lactamase inhibitor. This combination is particularly effective for treating various conditions such as intra-abdominal infections, nosocomial pneumonia, and community-acquired pneumonia. However, patients with any reported histories of allergic reactions to penicillins, cephalosporins, or similar agents are contraindicated from using this product.
Based in Bethlehem, Pennsylvania, B. Braun Medical Inc. is at the forefront of advancements in smart infusion therapy and pharmacy products, focusing on patient and provider safety. The company is dedicated to helping health systems enhance patient outcomes through innovative solutions. With a workforce exceeding 8,500 across over 30 North American locations, and part of the global B. Braun Group, the company is positioned as a leader committed to reducing healthcare costs while improving care delivery.
For further information on the DUPLEX Drug Delivery System and its innovative medication solutions, please visit B. Braun's official website.
The DUPLEX Drug Delivery System is engineered to streamline the medication administration process. The system features a two-compartment container that maintains a pre-measured antibiotic and diluent separately until the healthcare provider is ready to deliver the dosage. By simply folding, squeezing, and shaking the container, medical professionals can efficiently reconstitute the medication at the bedside. This unique set-up reduces the time taken to prepare each dose by nearly four minutes, which translates to substantial labor savings for healthcare workers compared to both the Baxter Mini-Bag Plus Container System and traditional compounding.
Beyond efficiency, the DUPLEX system aims to enhance safety for patients. Its closed-system architecture significantly lowers the risk of contamination and medication errors, with a noted decrease in errors by 54% relative to standard compounding methods. Impressively, no thawing is necessary, and the system's contents can be safely stored at room temperature or within automated dispensing units.
Jeremy Greene, Senior Director of Marketing at B. Braun Medical, emphasized the company's commitment to improving operational efficiency for healthcare providers while aligning with their overarching goal to safeguard patient welfare. “We are excited to introduce Piperacillin and Tazobactam in our innovative DUPLEX Drug Delivery System, designed to save time, labor, and space, and reduce waste,” Greene stated. He highlighted that the DUPLEX Container is crafted without DEHP or PVC, reinforcing B. Braun’s commitment to patient safety and environmental sustainability.
The launch of Piperacillin and Tazobactam in the DUPLEX Drug Delivery System represents B. Braun's second significant release this year, following the Cefazolin 3g introduction in similar configurations. Both reinforced the company's dedication to expanding its product offerings in response to the pressing demand for effective medications. As the company plans to unveil an array of injectable drugs in the subsequent years, it strives to bolster its portfolio to meet evolving patient needs.
Piperacillin and Tazobactam for Injection and Sodium Chloride Injection combines the efficacy of piperacillin, a member of the penicillin antibiotic class, with tazobactam, a beta-lactamase inhibitor. This combination is particularly effective for treating various conditions such as intra-abdominal infections, nosocomial pneumonia, and community-acquired pneumonia. However, patients with any reported histories of allergic reactions to penicillins, cephalosporins, or similar agents are contraindicated from using this product.
Based in Bethlehem, Pennsylvania, B. Braun Medical Inc. is at the forefront of advancements in smart infusion therapy and pharmacy products, focusing on patient and provider safety. The company is dedicated to helping health systems enhance patient outcomes through innovative solutions. With a workforce exceeding 8,500 across over 30 North American locations, and part of the global B. Braun Group, the company is positioned as a leader committed to reducing healthcare costs while improving care delivery.
For further information on the DUPLEX Drug Delivery System and its innovative medication solutions, please visit B. Braun's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.